Vaccines for biodefense and emerging and neglected diseases

Other titles
  • Elsevier ScienceDirect.
  • Elsevier ebook collection.
  • 1st ed.
  • Amsterdam ; Boston : Academic 2009
Physical description
1 online resource (1519 p.)
  • 1-282-28744-3
  • 9786612287442
  • 0-08-091902-2
  • Description based upon print version of record.
  • Includes bibliographical references and index.
  • Reproduction available: Electronic reproduction. Amsterdam : Elsevier Science & Technology, 2008. Mode of access: World Wide Web. System requirements: Adobe Acrobat Reader or other PDF reader (latest version recommended); Internet Explorer or other browser (latest version recommended). Title from title screen (viewed on Sep. 8, 2008).
  • Mode of access: World Wide Web.
  • English
  • Description based on print version record.
  • Front Cover; Vaccines for Biodefense and Emerging and Neglected Diseases; Copyright Page; Contents; Preface; Foreword; Contributors; SECTION I: BIOTHREATS AND EMERGING INFECTIOUS DISEASES; Chapter 1. Agents of Emerging Infectious Diseases; Introduction; Emerging infectious diseases since 1967; Emerging infections causing acute respiratory infections; Viral pulmonary syndromes; Bacterial pulmonary syndromes; Emerging encephalitic syndromes; Arthropod transmitted bacterial diseases; Emerging enteric pathogens; Other emerging bacterial pathogens
  • Group A ╬▓-hemolytic streptococcal (GABHS) infectionsEmerging chronic viral diseases; Bioterrorism as a mechanism of emergence of infectious disease; Rationale for vaccines against emerging infectious diseases; The challenge of developing vaccines against emerging and re-emerging infectious diseases; Chapter 2. Bacterial Biothreat Agents; Introduction; Past uses of bacterial pathogens to deliberately cause disease; Potential for airborne bacterial pathogens to cause disease; Vaccines and antibiotics for the prevention and treatment of disease
  • Available vaccines against bacterial biothreat agentsNew vaccines and new vaccine technologies; Conclusions; Chapter 3. Viral Biothreat Agents; Introduction; The spectrum of biological threats; Viruses of concern; Preparedness; Conclusions; SECTION II: FUNDAMENTAL ASPECTS OF VACCINOLOGY; Chapter 4. Vaccine Development Pathway; Introduction; Market need; Basic science discoveries; Concept development; Create prototype product; Preclinical assessment; Manufacturing scale-up and current good manufacturing practices (cGMP); Investigational new drug (IND) application
  • Clinical assessment (phase 1, 2, and 3 testing)BLA-licensure; Immunization recommendations/implementation; Post-marketing surveillance; Chapter 5. Immunology of Vaccines: Consideration of the Neonate as a Target for Vaccination; Introduction; Neonatal responses to vaccination: lessons from animal models; Chapter 6. Molecular Approaches to Bacterial Vaccines; Reverse vaccinology; Functional genomics and proteomics; Bacterial cell surface display systems; Novel delivery systems; Genetic approaches; Conclusions; Chapter 7. Viral Vectors; Introduction; Adenovirus; Adeno-associated virus
  • AlphavirusesNewcastle disease virus; Poxviruses; Vesicular stomatitis virus; Other viruses; Conclusions; Chapter 8. DNA Vaccines for Biodefense and Emerging and Neglected Infectious Diseases; Introduction; Advancements in DNA vaccine technology; Representative DNA vaccines for biodefense and emerging infectious diseases; Conclusions; Chapter 9. Vaccine Adjuvants; The requirement for vaccine adjuvants; Freund's adjuvant and aluminum salts; Adjuvant mechanisms; Additional adjuvant characteristics and mechanisms; Side effects of widely used human adjuvants
  • Chapter 10. Preclinical Vaccine Development: Implementing the Food and Drug Administration's Good Laboratory Practices in a Biocontainment Environment-A University BSL3/BSL4 Laboratory Perspective
Related item
  • Bibliography
  • Electronic books.
  • Illustrated
  • text
  • UK eLD e-books
  • English


  • The last 20 years has seen a rapid increase in infectious diseases, particularly those that are termed ""emerging diseases"" such as SARS, ""neglected diseases"" such as malaria and those that are deemed biothreats such as anthrax. It is well-recognized that the most effective modality for preventing infectious diseases is vaccination. This book provides researchers with a better understanding of what is currently known about these diseases, including whether there is a vaccine available or under development. It also informs them of what they need to do if they are currently working on develop